Strategic report seeks urgent IP reforms in Australia
This article was originally published in Scrip
Executive Summary
The same week it bemoaned market conditions for pharma firms, the R&D-based industry association, Medicines Australia, has applauded a government backed report outlining a 10-year strategic health and medical research plan for Australia. The clearest call in the report is for Australia’s intellectual property system should be harmonized with international standard by extending the term of pharmaceutical data exclusivity. The report itself says its plan should be treated as an urgent national priority. And Medicines Australia agrees: CEO Brendan Shaw said the recommendations deserved bi-partisan support and that they should be implemented "expeditiously.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.